secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001558370-23-001226
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix receives FDA Refusal to File for HyBryte NDA in CTCL
--------------------------------------------------------------

- FDA issued Refusal to File (RTF) letter for HyBryte NDA for early-stage cutaneous T-cell lymphoma.
- NDA submitted Dec 14, 2022 deemed not sufficiently complete for substantive review.
- Soligenix plans to request a Type A meeting to clarify issues and seek guidance for resubmission.
- Cutaneous T-cell lymphoma is a rare cancer affecting over 25,000 patients in the U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837023001226/0001558370-23-001226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837023001226/tmb-20230214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer